三重激動劑 Retatrutide Retatrutide
B 2 C 1
適應症與證據等級
法規與權威立場 (L4)
L4a · US FDA
立場：cautious
Retatrutide is not currently approved by the FDA and is considered an investigational medication, with Eli Lilly currently evaluating its safety and efficacy in clinical trials.
來源 ↗ L4b · EU EFSA
立場：neutral
Retatrutide is not currently approved by the FDA and is considered an investigational medication.
來源 ↗ L4c · UK NHS
立場：not_addressed
L4d · TW TFDA / 衛福部
立場：cautious
Retatrutide is not currently approved by the FDA and is considered an investigational medication, with Eli Lilly currently evaluating its safety and efficacy in clinical trials.
來源 ↗ L4e · WHO
立場：not_addressed
市場與行銷 (L10)
L10a · TW Market Channels
L10b · TW Legal Identity (TFDA)
L10c · TW Community (PTT/Dcard/Mobile01)